Overview

High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This trial studies how well high dose vitamin A compound works in treating participants with non-small cell lung cancer that can be removed by surgery. Vitamin A compound may increase the number of germinal centers (immune centers that make antibodies mature) in tumor and lymph tissues which may be beneficial to patients with cancer.
Phase:
Early Phase 1
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborator:
National Cancer Institute (NCI)
Treatments:
Anti-Infective Agents
Corticosterone
Fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether
Retinol palmitate
Vitamin A
Vitamins